Monoclonal antibodies with enhanced ADCC function
US10081683B2 · kind B2 · utility
0Cited by
18References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 7, 2017 |
| Grant date | Sep 25, 2018 |
| Priority date | — |
| Expiry date | Jun 7, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/732
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunization in Rh negative persons, in particular for hemolytic disease in a new-born baby of for uses such as idiopathic thrombocytopenic pupura 9ITP).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.